Basic Dasatinib Information

• INN (International Nonproprietary Name): Dasatinib
• Brand names available in Australia: Sprycel
• ATC Code: L01EA02
• Forms & dosages: Tablets (20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg)
• Manufacturers in Australia: BMS Australia Pty Ltd
• Registration status in Australia: Schedule 4 (S4) - Prescription only
• OTC / Rx classification: Prescription only

Critical Warnings & Restrictions

Dasatinib is an effective treatment for specific types of leukaemia, predominantly targeting Philadelphia chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) and acute lymphoblastic leukaemia (ALL). However, awareness of critical warnings and restrictions surrounding its use is vital, especially for vulnerable groups.

High-Risk Groups

Identifying high-risk patients is crucial when prescribing dasatinib. Several groups must be particularly monitored during treatment:

• Elderly Patients: Older adults often exhibit increased sensitivity to dasatinib, necessitating closer observation to detect any adverse reactions promptly.
• Pregnant Patients: Dasatinib poses a significant teratogenic risk; pregnant individuals must avoid this medication entirely.
• Chronic Illnesses: Patients with chronic conditions such as cardiovascular disease, liver impairment, or a history of arrhythmias should only be treated with dasatinib under strict medical supervision. Dosage adjustments may be necessary to ensure their safety while managing their leukaemia effectively.

Interaction With Activities

Dasatinib can impair cognitive and motor functions, raising concerns about activities that require full attention, such as driving or operating machinery. Under Australian law, it is essential to evaluate one’s ability to safely perform these tasks while undergoing treatment.

Patients are encouraged to consult their healthcare provider regarding potential impairments linked to dasatinib. Such discussions are vital for tailored advice based on individual health assessments, ensuring personal safety and compliance with legal obligations.

Q&A — “Can I Drive After Taking It in Australia?”

Q: Can I drive after taking dasatinib in Australia?
A: It’s advisable to avoid driving until you know how dasatinib affects you, as it can impair your ability to drive safely.

Usage Basics

The fundamental information about dasatinib, regarding usage and availability, is essential for patients considering this treatment option. Understanding how the medication is classified, marketed, and prescribed aids in navigating the healthcare landscape effectively.

INN, Brand Names Available in Australia

Dasatinib, more commonly known through its brand name, Sprycel, is the International Nonproprietary Name (INN) for this medication. In Australia, it comes in various strengths, including:

• 20 mg
• 50 mg
• 70 mg
• 80 mg
• 100 mg
• 140 mg

Each form of dasatinib is available via prescription at local pharmacies, making it accessible for Australian patients seeking treatment for their leukaemia.

Legal Classification

Dasatinib is classified under Schedule 4 (S4) by the Therapeutic Goods Administration (TGA) in Australia, signalling that it is a prescription-only medication. This classification ensures that patients are monitored by healthcare professionals while undergoing treatment.

Furthermore, dasatinib is listed on the Pharmaceutical Benefits Scheme (PBS), which offers subsidised access for eligible patients. This financial support significantly eases the burden of cancer treatment, making essential medications more affordable and accessible across Australia.

Interaction Chart

Patients embarking on dasatinib treatment need to be aware of various food and drink interactions that may affect their health outcomes. Certain dietary choices in Australia could lead to unexpected side effects when combined with dasatinib.

Food and drinks (alcohol, coffee, Australian diet context)

While incorporating dasatinib into a treatment regimen, moderation with specific food and beverage choices is crucial:

• Alcohol: Limit intake to avoid intensified side effects like dizziness and fatigue.
• Caffeine: Common in Australian diets; managing coffee consumption is advisable as it may amplify dasatinib's nervous system effects.

Maintaining a balanced diet and ensuring communication with healthcare providers regarding dietary habits can support overall health while undergoing treatment.

Common drug conflicts

Dasatinib can have interactions with various medications, particularly those processed by the CYP3A4 enzyme pathway. This means that patients must be vigilant about what they mix with their treatment protocol. Examples of potential conflicts include:

• Antibiotics: Certain classes of antibiotics can interfere with how dasatinib works.
• Antifungals: Medications in this category may alter dasatinib's efficacy.
• Anticonvulsants: These drugs can also impact the metabolism of dasatinib.

Communication with healthcare providers about all current medications is essential. This conversation ensures proper adjustments can be made to avoid adverse effects or diminished effectiveness.

User Reports & Trends

Insights from Australian patients indicate a spectrum of experiences with dasatinib. Many share stories of significant improvement in managing leukaemia, with manageable side effects being a common theme.

Feedback from users

Online health platforms like ProductReview serve as valuable resources for patient testimonials. Many highlight the importance of maintaining clear communication with healthcare providers to personalise treatment plans. This connection fosters confidence in managing their health effectively.

Access & Purchase Options

Obtaining dasatinib is relatively straightforward in Australia, with several easy access points for patients needing this critical medication.

National chains (Chemist Warehouse, Priceline, TerryWhite)

Major pharmacy chains across Australia, such as Chemist Warehouse, Priceline, and TerryWhite Chemmart, stock dasatinib under brand names like Sprycel. Accessible through prescription, these pharmacies provide a platform for consultations, ensuring patients grasp their medication regimen entirely.

Online pharmacies and telehealth e-prescriptions

For many, convenience is key. Online pharmacies are increasingly popular, especially for those in remote areas. Telehealth prescriptions streamline access to dasatinib without the need for frequent travel, allowing patients to stick to their treatment plans efficiently.

Mechanism & Pharmacology

Understanding how dasatinib works can demystify the treatment process for patients.

Simplified explanation

Dasatinib acts as a targeted oral antineoplastic agent. It specifically inhibits BCR-ABL and SRC-family tyrosine kinases. By disrupting these pathways, dasatinib hinders cancer cells’ ability to proliferate and survive effectively. This targeted approach often results in fewer side effects compared to traditional chemotherapy methods, enhancing the quality of life for patients.

Clinical terms

For healthcare professionals, the mechanism involves blocking multiple vital pathways necessary for cancer cell survival. Dasatinib's selectivity yields a high therapeutic index. Clear communication regarding its role in cancer management is vital, as it helps patients understand the significance of their treatment plan.

Indications & Off-Label Uses

Dasatinib is primarily approved by the Therapeutic Goods Administration (TGA) of Australia for treating Philadelphia chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in both adult and paediatric populations. It's also indicated for Ph+ acute lymphoblastic leukaemia (ALL). These approvals ensure patients have access to a medication that has demonstrated efficacy and safety in treating these conditions, securing better health outcomes.

Approved indications by TGA

The TGA has placed significant emphasis on the therapeutic advantages of dasatinib for patients diagnosed with Ph+ CML and ALL, making it a vital choice for oncologists. Under Australia's medical framework, dasatinib is recognised as an essential tool in the fight against these leukaemias. Approval reflects rigorous clinical trials proving the drug's effectiveness, which fosters confidence among healthcare providers in medication management for these serious conditions.

Off-label uses in Australian clinical practice

Clinical practice in Australia also sees dasatinib utilised off-label, particularly for patients exhibiting resistance to first-line treatments such as imatinib. Oncologists may consider dasatinib in unique clinical circumstances, often under compassionate use principles. Patients contemplating dasatinib for off-label uses are encouraged to have thorough discussions with their healthcare providers to weigh the risks and benefits, ensuring informed decisions are made with their full understanding.

Key Clinical Findings

Recent studies conducted between 2022 to 2025 indicate that dasatinib continues to play a critical role in the ongoing fight against CML and ALL.

Notable findings from real-world applications reveal:

• Improved patient outcomes.
• Manageable side effects.
• Extended survival rates.

These results showcase the drug’s significant efficacy as a cornerstone treatment in Australian oncology practice, emphasising the shift towards adapting therapies that are not only effective but also well-tolerated by patients.

Alternatives Matrix

PBS-listed alternatives comparison table

Pros and cons checklist

• Pros: Efficacy in targeted therapy, less cytotoxicity than chemotherapy, PBS reimbursement available.
• Cons: Side effects, monitoring required for high-risk patients, potential drug interactions.

Common Questions

Patients often have numerous inquiries when it comes to dasatinib. Common questions include:

• What side effects should I be aware of?
• Are there dietary restrictions while taking dasatinib?
• How should I manage a missed dose?

Understanding these aspects greatly enhances the experience of patients and reassures them about their treatment options. Consulting healthcare professionals provides clarity, ensuring potential concerns are addressed meaningfully.

Suggested Visual Content

Creating visually engaging infographics can significantly aid patient education. Key suggestions include:

• Infographics illustrating PBS pricing structures for dasatinib.
• A network map displaying pharmacy locations across Australia that stock dasatinib.

These resources will facilitate patient navigation and access to this essential cancer treatment, helping to demystify the process and improve overall understanding.

Registration & Regulation

TGA approval

The TGA’s endorsement of dasatinib signifies its safety and efficacy as a formidable treatment for Ph+ CML and ALL. This regulatory framework supports healthcare professionals by providing guidelines that align with best practices in medication management, ensuring patient safety and optimal outcomes.

PBS subsidy details

Dasatinib's inclusion in the Pharmaceutical Benefits Scheme (PBS) allows for structured pricing and reimbursement arrangements, making treatment more accessible for eligible patients. This commitment to affordable cancer care exemplifies Australia’s dedication to enhancing health outcomes for those battling these challenging conditions.

Storage & Handling

Household storage in Australian climate

In Australia’s diverse climate, storing dasatinib properly is crucial to maintaining its efficacy. It should be stored at room temperature (15–30°C) away from light and moisture. Patients should be educated on these guidelines to prevent degradation, ensuring medication remains potent and safe.

Cold-chain handling for pharmacies

Pharmacies are responsible for observing strict handling protocols for dasatinib to preserve its integrity. Maintaining optimal storage conditions protects the medication’s quality, reflecting the commitment to delivering safe and effective treatments to patients relying on this regimen.

Guidelines for Proper Use

Australian pharmacist counselling style

Pharmacists in Australia play an indispensable role in counselling patients regarding dasatinib usage. They furnish patients with comprehensive insights about potential side effects, drug interactions, and lifestyle adjustments necessary for effective management of their treatment.

Patient advice from PBS and national health authorities

Public health guidelines emphasise the importance of educating patients about dasatinib. This includes understanding treatment aims, the significance of adherence to medication, and regular health status monitoring. Such directives align with national strategies prioritising improved health outcomes for cancer patients.

Delivery Times for Dasatinib